February 5, 2020

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Category: Article Summary

Topic: Testing and Treatment

• Using BenevolentAI, knowledge of coronavirus receptors, and assumptions about vulnerable cell types, Richardson, et al. assess AP2-associated protein kinase 1 (AAK1) inhibitors for potential 2019-nCoV therapeutic use. They identify baricitinib as a candidate for trials based on its plasma concentration at therapeutic doses.

Richardson, et al. (Feb 3, 2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. https://doi.org/10.1016/S0140-6736(20)30304-4